Lutein and Zeaxanthin

What it is

Lutein and zeaxanthin are carotenoid pigments that humans cannot make; they come from food or supplements [1]. They concentrate at the center of the retina (the macula), where they form the macular pigment [1] [2]. Dietary sources include leafy green vegetables, yellow corn products and egg yolks, and goji berries have the highest known zeaxanthin content [1]. Supplements commonly provide 10 mg of lutein with 2 mg of zeaxanthin — the AREDS2 dose — alone or in eye-health formulas [3].

How it might work

Proposed, not established: the pigments are thought to protect the retina by filtering blue light and acting as antioxidants where light exposure causes oxidative stress [1] [2]. How much they accumulate can be measured non-invasively as macular pigment optical density (MPOD) [1].

What the research says

Macular pigment. A 2021 meta-analysis of 46 studies (3,189 adults with healthy eyes) found no significant pigment change below 5 mg a day of lutein/zeaxanthin, a pooled rise of 0.04 units at 5 to under 20 mg a day, and 0.11 units at 20 mg or more, over 3 to 12 months [2]. A 2024 network meta-analysis — a review that compares many treatments, including ones never tested head to head — pooled 38 of 60 randomised trials and found every supplement group raised macular pigment against placebo [4]. The best-ranked product was lutein plus zeaxanthin plus omega-3 (99.3% probability), ahead of lutein plus zeaxanthin alone (68%) [4]. The authors rated most of this evidence low quality because of indirectness and signs of publication bias [4].

Macular degeneration. The disease-outcome evidence centers on the AREDS formula (vitamins C and E, zinc, and beta-carotene or lutein/zeaxanthin). A 2023 Cochrane review of 26 trials (11,952 people) found the formula probably slows progression to late AMD in people with intermediate AMD: about 78 fewer cases per 1,000 over six years (26 to 126 fewer) [5]. In AREDS2's 10-year follow-up, lutein/zeaxanthin cut progression to late AMD by 9% and did better than the beta-carotene it replaced (HR 0.85), which nearly doubled lung-cancer risk [6]. A 2025 post-hoc analysis found the supplements slowed geographic atrophy's spread toward the fovea — the retina's center — but the total area of damage was unchanged [7]. For preventing AMD in healthy eyes, a 2017 Cochrane review found no evidence on lutein and zeaxanthin [8].

Vision function. In the network meta-analysis, glare recovery (how fast vision rebounds after a bright flash) improved with lutein plus zeaxanthin, and contrast sensitivity improved only at low spatial frequency (coarser patterns), while visual acuity improved only with an antioxidant mixture plus omega-3 and lutein [4].

Doses used in studies

AREDS2 used 10 mg of lutein plus 2 mg of zeaxanthin a day [3]. Across the trials in the 2024 network meta-analysis, lutein or zeaxanthin doses ranged from 2 mg to 20 mg or more a day, given for 6 weeks to 4 years [4]. In the dose-response analysis, clear pigment rises appeared from 5 mg a day and were largest at 20 mg or more [2]. These are study doses, not recommendations.

Safety and interactions

Common side effects. The trials we read did not report serious side effects from lutein and zeaxanthin [6] [5], though most studies were too small to detect rare harms [5].

Upper limits. A European Food Safety Authority review set an acceptable daily intake of 1 mg per kg of body weight for lutein as a food additive — about 70 mg for a 70 kg adult, well above supplement doses — using a large safety margin because long-term animal studies are missing [9].

Medicine interactions. We found no studies of lutein or zeaxanthin interactions with medicines, and the trials we read did not report any.

Pregnancy and breastfeeding. Pregnancy and breastfeeding may lower lutein and zeaxanthin supply for mother and baby [1]; we found no safety trials in these groups.

Eye formula cautions. AREDS-style formulas combine several nutrients, and taking one alongside a regular multivitamin can push vitamin A and zinc above their tolerable upper intake levels [10]. Beta-carotene — what lutein/zeaxanthin replaced in the eye formula — raises lung-cancer risk in people who smoke or used to smoke [6] [3].

Caveats and open questions

The pigment results are surrogate outcomes: denser macular pigment is a marker, not proof that vision loss was prevented [4] [2]. In AREDS2's original five-year analysis, lutein/zeaxanthin did not significantly reduce progression; the 9% reduction appeared with longer follow-up [3] [6]. The geographic-atrophy finding is a post-hoc analysis [7]. The clearest formula benefit is in people who already have intermediate AMD; whether supplements prevent AMD in healthy eyes is not settled [5] [8]. Trials tested specific products and doses, which may not match a given label [4].